Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
11. April 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
PV-10 demonstrated significant anti-tumor activity in vivo in head and neck cancers KNOXVILLE, TN, April 11, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the...